title: A randomized study of mitoxantrone plus cytarabine versus daunomycin plus cytarabine in the treatment of previously untreated adult patients with acute nonlymphocytic leukemia.
abstract: Between May 1985 and November 1988, 143 adult patients with previously untreated acute nonlymphocytic leukemia were randomized to receive mitoxantrone and cytarabine (MTT+Ara-C) or daunomycin and cytarabine (DNM+Ara-C) in order to compare the efficacy and acute and chronic toxicities. Therapy consisted of 3 days of MTT 12 mg/m2/i.v. or DNM 45 mg/m2/i.v.; both groups received Ara-C 100 mg/m2 daily by continuous infusion (CI) for 7 days. Those who failed to achieve a complete remission after one induction course received a second induction course for 2 and 5 days at the same doses. All the patients who achieved complete remission received two consolidations of 2 days of MTT or DNM and 5 days of Ara-C in CI at the same dose as for induction. Of the 72 patients on MTT+Ara-C, 38 (53%) achieved complete remission, compared with 29 (43%) of 67 treated with DNM+Ara-C. Three and 5 patients had partial remission, 7 and 18 failed to respond, 24 and 15 died in the first 21 days of induction, of those treated with MTT+Ara-C or DNM+Ara-C, respectively (p = 0.34). Median duration of complete remission and survival was 185 and 103 days or 165 and 160 days, respectively (p = 0.85). More early deaths were observed with MTT+Ara-C due to greater myelosuppression, and a higher incidence of failure with DNM+Ara-C. No significant differences between treatment groups were observed in 21 categories of adverse events. The results demonstrate similar incidence of complete response, length of duration of complete remission, overall survival, and toxicity with MTT+Ara-C and DNM+Ara-C.
authors.affiliation: Centro de Internación e Investigación Clinica, Angelica Ocampo, Buenos Aires, Argentina.
authors.forename: S
authors.initials: S
authors.lastname: Pavlovsky
authors.forename: J
authors.initials: J
authors.lastname: Gonzalez Llaven
authors.forename: M A
authors.initials: MA
authors.lastname: Garcia Martinez
authors.forename: P
authors.initials: P
authors.lastname: Sobrevilla
authors.forename: M
authors.initials: M
authors.lastname: Eppinger-Helft
authors.forename: A
authors.initials: A
authors.lastname: Marin
authors.forename: M
authors.initials: M
authors.lastname: López-Hernández
authors.forename: I
authors.initials: I
authors.lastname: Fernandez
authors.forename: M E
authors.initials: ME
authors.lastname: Rubio
authors.forename: S
authors.initials: S
authors.lastname: Ibarra
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects; D003630:Daunorubicin / Q000008:administration & dosage / Q000009:adverse effects; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008942:Mitoxantrone / Q000008:administration & dosage / Q000009:adverse effects; D013997:Time Factors
chemical_list: D003561:Cytarabine; D008942:Mitoxantrone; D003630:Daunorubicin